Stress Hyperglycemia as First Sign of Asymptomatic Type 1 Diabetes: An Instructive Case and Literature Review

doi:10.21203/rs.3.rs-229675/v1

PDF

Case report

Stress Hyperglycemia as First Sign of Asymptomatic Type 1 Diabetes: An Instructive Case and Literature Review

https://doi.org/10.21203/rs.3.rs-229675/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted 22 Feb, 2021

You are reading this latest preprint version

Background:

Stress hyperglycemia (SH) is considered a transient manifestation and routine diagnostic evaluation was thought to be unnecessary due to the lack of definite correlation with diabetes mellitus (DM). Although SH was usually benign and long-term treatment was superfluous, it might be the first sign of insulinopenic status such as type 1 DM (T1DM).

Case presentation:

We reported a boy with acute asthma attack presented incidentally with high blood glucose levels exceeding 300 mg/dL and obvious glycemic variability. Sustained hyperglycemic duration lasting longer than 48 hours was also noticed. To elucidate his unique situation, glucagon test and insulin autoantibody survey were done which showed insulinopenia with positive anti-insulin antibody and glutamic acid decarboxylase antibody despite the absence of overt DM symptoms and signs.

Conclusions:

This case highlights that SH might be a prodromal presentation in T1DM children, especially when accompanied simultaneously with extreme hyperglycemia, apparent glucose variability, as well as prolonged hyperglycemic duration.

Pediatrics

children

hyperglycemia

stress

type 1 diabetes mellitus

Stress hyperglycemia (SH) is a common clinical manifestation in children with acute illness. It is caused by the increased levels of cortisol, catecholamine and proinflammatory cytokines (TNF-α, IL-1 and IL-6) mediated by the hypothalamic-pituitary-adrenal axis and the sympathoadrenal system. Since the physiological response of SH increases the glucose uptake of the brain and immune system at a time of stress which in turn enhances the chances of survival, the meticulous investigation and aggressive management to SH were thought to be unnecessary in clinical practice¹. The prevalence of hyperglycemia, defined as glucose level ≧ 150 mg/dl, has been reported to be ranged from 3.8–4.9% children in the emergency department^2–4. On the other hand, among ill children in intensive care unit (ICU), SH accounted for 36.6% and 44.5% of them at the initial time and within 24 hours of the admission, respectively⁵. Because the SH seems associated with the severity of underlying disease, it was usually regarded as a benign phenomenon in acute illness. However, whether the coexistence of other pathogenic etiology could mask or aggravate SH has never been emphasized in the literature.

Previous studies showed no obvious association between SH and type 1 diabetes mellitus (T1DM)^{2, 3, 6–10} (Table 1); therefore, the routine workup for children with SH to confirm T1DM is not recommended while there is no overt signs and/or symptoms of DM. To add a new dimension to the physiological role of SH, we herein reported an asthmatic boy having unique SH with manifestations of extreme hyperglycemia, glucose variability (GV), and prolonged hyperglycemic duration, finally confirmed as T1DM. This instructive case highlights an unusual pattern of SH with possible hidden pathogenesis and further investigation should be considered for precise early diagnosis to prevent subsequent diabetic ketoacidosis.

An 8-year-2-month old Taiwanese boy presented with dyspnea for one day. He had no preceding symptoms such as polyphagia, polydipsia, polyuria, or body weight loss during this episode. His past medical history is notable for bronchial asthma and allergic rhinitis without using regular medication. Family history revealed no T1DM or T2DM in family members. Two days before admission, he was noted to have runny nose, productive cough and fever. He was treated with antitussives and antipyretics at a local clinic initially. Because dyspnea along with decreased oral intake was noticed one day later, he was sent to primary healthcare center where inhaled terbutaline sulfate and intramuscular dexamethasone were given in consideration of acute exacerbation of bronchial asthma (AEBA). After treatment, laboratory tests showed no acidosis or alkalosis; however, hyperglycemia was noticed (Table 2). Owing to persistent dyspnea, he was referred to our hospital.

Table 2

Laboratory data of patient
At primary healthcare center
Biochemistry		Venous blood gas analysis
Glucose 381 mg/dL	(70-100)	pH 7.391			(7.32-7.43)
Na⁺ 133 mmol/L	(136-145)	PvCO₂ 31 mmHg			(38-49)
K⁺ 4.3mmol/L	(3.5-5.1)	PvO₂ 53.4 mmHg			(30-50)
Ketone 0.7 mmol/L	(< 0.6)	HCO₃ 19.0 mmol/L			(22-29)
CRP 0.5 mg/dL	(< 0.8)	BE -4.4 mmol/L			(-4-+2)
On admission
BH 127 cm (25-50^th percentile), BW 23 kg (15^th percentile), BT 37.1°C, HR 116 beats/min RR 32 breaths/min, BP 115/64 mmHg, SpO₂ 99% (nasal cannula with O₂ flow rate 3L/min)
Blood cell count				Urinalysis
WBC 10690/μL	(4000-12000)			pH 5.0	(4.5-8.0)
Hb 13 g/dL	(11.5-14.5)			Glucose 4+	(negative)
Plt 25.8 × 10⁴/μL	(15 × 10⁴-40 ×10⁴)			Ketone body 2+	(negative)
Neutrophil 91%	(54-62)			Occult blood —	(negative)
Lymphocyte 6.7%	(25-33)			Strip WBC —	(negative)
Biochemistry			Arterial blood gas analysis
Glucose 373 mg/dL	(70-100)			pH 7.318	(7.35-7.45)
Na⁺ 134 mmol/L	(136-145)			PaCO₂ 49 mmHg	(35-45)
K⁺ 4.1mmol/L	(3.5-5.1)			PaO₂ 67.6 mmHg	(75-100)
Cl^- 98 mmol/L	(98-107)			HCO₃ 24.8 mmol/L	(21-28)
AST 14 IU/L	(< 50)			BE -1.8 mmol/L	(-4-+2)
ALT 8 IU/L	(< 45)			SaO₂ 92%	(>95)
BUN 12 mg/dL	(5-18)
Cre 0.5 mg/dL	(0.3-0.7)
Ketone 0.9 mmol/L	(< 0.6)
HbA1C 7.7%	(4.0-5.7)
Islet autoantibodies				Glucagon stimulation test
Insulin Ab 5.7% B/T	(< 5.5)			Time C-peptide
Anti-GAD 7.5 U/mL	(< 1.0)			0 minute 0.43 ng/ml	(> 0.5)
Anti-TPO 15.2 U/mL	(< 35)			6 minute 1.16 ng/ml	(>1.8)
Anti-TG 5.0 U/mL	(< 20)
Ab, antibody; Anti-GAD, anti-glutamic acid decarboxylase antibody; Anti-TPO, anti-thyroid peroxidase antibody; Anti-TG, anti-thyroglobulin antibody; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BE, base excess; BH, body height; BP, blood pressure; BT, body temperature; BUN, blood urea nitrogen; BW, body weight; Cl^-, chloride; Cre, creatinine; CRP, C-reactive protein; Hb, hemoglobin; HbA1C, hemoglobin A1c; HR, heart rate; K⁺, potassium; Na⁺, sodium; Plt, platelet; RR, respiratory rate; SaO₂, arterial oxygen saturation; SpO₂, O₂ saturation by pulse oximetry; WBC, white blood cells

On examination, use of accessory muscle and bilateral diffuse wheezing were noticed. There was no acanthosis nigricans over posterior neck or axillae. The thyroid was non-palpable. Laboratory tests showed hyperglycemia, ketonuria and ketonemia (Table 2). Chest radiograph revealed bilateral pulmonary infiltration. Under impression of AEBA, he was admitted to pediatric ICU (PICU).

On observing hyperglycemia, exclusively half-normal saline was infused on the first day of hospitalization. Inhaled beta-2 agonists and intravenous corticosteroids were also given. Nevertheless, blood glucose monitoring disclosed fluctuating hyperglycemia. Although this SH might result from AEBA per se and/or medication, his baseline blood glucose levels were inexplicably higher than 150 mg/dL within the first 24 hours and frequently rose above 300 mg/dL or even 400 mg/dL (Fig. 1). The delta blood glucose levels (△BG) could reach 150 to 300 mg/dL in a single hour, suggesting extremely high GV. Moreover, blood glucose exceeding 150 mg/dL could be detected even at 48 hours after admission, indicating prolonged hyperglycemic duration. To elucidate this unusual fluctuation of glucose values, further investigations were done which showed increased hemoglobin A1c (HbA1c), positive islet autoantibodies, and insulinopenia in glucagon test (Table 2). Finally, he was diagnosed as T1DM despite the absence of classical DM symptoms.

SH is regarded as benign and transient hyperglycemia during acute stress. Accumulating studies have demonstrated that SH was unrelated to T1DM, thus rendering routine confirmatory investigation unnecessary^{2, 3, 6–10}. Furthermore, extreme SH (ESH), glucose levels ≥ 300 mg/dL, was rarely seen in children; and it was also unrelated to subsequent DM¹⁰. Crucially, previous studies showed the ESH subjects exhibited merely 13% ketonuria¹⁰. In view of this, ketonuria in our young boy might be taken as a feature of glucose dysregulation in that ketone body forms rapidly in insufficient insulin environment. However, the critical timing to elucidate the underlying etiopathology of SH was still inconclusive, the current latent T1DM case is thus an exceptional didactic experience worthy of attention.

In addition to AEBA per se, beta-2 agonists and corticosteroids also increase blood glucose mediated by promoting gluconeogenesis. Accordingly, previous studies regarding SH almost excluded beta-2 agonists and corticosteroids intervention^{2, 3, 8, 9}; therefore, asthmatic children with underlying DM might be excluded and then underestimated. Interestingly, asthma and T1DM are both immune-mediated disease but their association was not fully clarified. It was reported that children with asthma increase the risk of subsequent T1DM development by 41% when compared to normal population¹¹. To date, there were only two studies on a total of 33 asthmatic children exploring the relationship between transient hyperglycemia and asthma, but none of the subjects was diagnosed to have DM eventually^{7, 10}.

Likewise, in our patient, bronchodilator and steroid might contribute to hyperglycemia and aggravate the severity of SH; hence, drug effect on glucose metabolism should be taken into consideration. Burgess C. et al. reported that only high doses of inhaled beta-2 agonist can significantly increase blood glucose to the peak level of 133 mg/dL after 5 hours of treatment in mild-to-moderate asthma subjects¹². Another study showed that asthmatic patients had a peak value of glucose 293 mg/dL after 4 hours of combined treatment with beta-2 agonist and corticosteroid¹³. In the present case, extreme values of blood glucose were inconsistent with the time point of beta-2 agonists and corticosteroids intervention (Fig. 1). Moreover, the inexplicably higher glucose concentration (≥ 300 mg/dL) than those in previous studies, which together supported that dysglycemia of our case might be caused not only by acute stress and drug effect but also by underlying insulinopenia. In addition to peak blood glucose, the duration of SH could be another crucial clue for early detection of latent DM. It has been reported that 67% of ESH subjects normalized their blood glucose levels below 150 mg/dL within 48 hours and none of them was subsequently diagnosed with DM¹⁰. Similarly, Gupta et al. also demonstrated the restoration of SH could be observed within 24 hours in all enrolled children with illness and the result of oral glucose tolerance tests done for 86% participants were normal². In the present case, blood glucose above 150 mg/dL was detected even at 48 hours after admission (Fig. 1), indicating that this prolonged SH might be caused by latent DM.

To elucidate the pattern of glucose fluctuation under psychiatric stress, T1DM animal models under a predator stress circumstance showed the SH was characterized as “fast and slow” pattern, in which blood glucose rapidly increased and slowly decreased thereafter¹⁴. Although we cannot fully extrapolate the animal results to humans, blood glucose levels of the present case indeed rapidly increased from 174 mg/dl to 400 mg/dL within 2 hours (9th -11th hours after admission), maintained peak levels above 400 mg/dL for 5 hours (11th -15th hours after admission) and then decreased slowly to 89 mg/dL (Fig. 1), suggesting a human “fast and slow” pattern along with prolonged SH course in insulinopenic status.

Although HbA1c was a pivotal biomarker of long-term glycemic control with the usefulness to reflect the cumulative glycemic history of the preceding two to three months¹⁵, it cannot tell GV to clinicians. It has been reported that GV was associated with diabetes complication and increased mortality rate in PICU^{16, 17}. Hanefeld et al. monitored blood glucose values with continuous glucose measurement systems (CGMS) in abnormal glucose tolerance subjects and control ones and demonstrated a significantly higher amplitude of glucose excursion and standard deviation (SD) in those with abnormal glucose tolerance, suggesting higher GV¹⁸. Another study focusing on children with positive islet autoantibodies (high risk to future T1DM) revealed those with blood glucose above 140 mg/dL accounted for over 20% study time during a 5- to 7- day -period of CGMS monitor could be used to predict the future development of DM. Compared to patients with negative antibody, a higher SD of blood glucose was noted in those with positive islet autoantibodies¹⁹.

Owing to unconfirmed diagnosis of DM at admission, regular stick blood glucose test was performed for our patient to evaluate his GV under stress instead of real-time CGMS. Significant change of blood glucose was noticed initially after stress exposure; however, obvious variation unexpectedly existed after the resolution of acute stress (Fig. 1). This interesting finding illuminated persistent high GV after stress might be a potent risk factor for underlying T1DM, but further study with more patients is needed to confirm our current findings.

To our knowledge, there has been no prospective study exploring the difference in SH between diabetic and nondiabetic children. This first case highlights an important but still complex relationship between SH (glucose dysregulation) and subclinical T1DM (insulinopenia). We suggest that clinicians should be aware of pathological SH, particularly when it was characterized by features such as ESH (> 300mg/dl), high GV even after acute phase of illness, prolonged hyperglycemic duration (longer than 48 hours) or ketonuria (urine ketone ≥ 2+), all suggesting that dysglycemia might result from latent diabetes. Then further investigations to traditionally benign SH should be conducted even there were no clinical signs or symptoms of diabetes.

AEBA: Acute exacerbation of bronchial asthma; CGMS: Continuous glucose measurement systems; DM: Diabetes mellitus; ESH: Extreme stress hyperglycemia; GV: Glucose variability; HbA1c: Hemoglobin A1c; ICU: Intensive care unit; PICU: Pediatric intensive care unit; SD: Standard deviation; SH: Stress hyperglycemia; T1DM: Type 1 diabetes mellitus

Ethics approval and consent to participate

Not applicable.

Consent for publication

Consent for publication from the parents was obtained.

Availability of data and materials

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported in part by a grant from the Research Fund of Tri-Service General Hospital (TSGH-E-I10187).

Authors' contributions

WDW conceptualized the study, collected data, drafted the initial manuscript, and reviewed and revised the manuscript. CHC, CHT, SYW, SYL collected data, carried out the initial analyses, and reviewed and revised the manuscript. CML conceptualized the study, coordinated and supervised data collection, and provided critical editing and revision to the final drafts of the report.

Acknowledgements

Not applicable.

Marik PE, Bellomo RJCC. Stress hyperglycemia: an essential survival response! 2013;17(2):305.
Gupta P, Natarajan G, Agarwal KJTIJoP. Transient hyperglycemia in acute childhood illnesses: to attend or ignore? 1997;64(2):205-10.
Bhisitkul DM, Morrow AL, Vinik AI, Shults J, Layland JC, Rohn RJTJop. Prevalence of stress hyperglycemia among patients attending a pediatric emergency department. 1994;124(4):547-51.
Valerio G, Franzese A, Carlin E, Pecile P, Perini R, Tenore AJAP. High prevalence of stress hyperglycaemia in children with febrile seizures and traumatic injuries. 2001;90(6):618-22.
Faustino EV, Apkon MJTJop. Persistent hyperglycemia in critically ill children. 2005;146(1):30-4.
Shehadeh N, On A, Kessel I, Perlman R, Even L, Naveh T, et al. Stress hyperglycemia and the risk for the development of type I diabetes. De Gruyter; 1997.
Herskowitz-Dumont R, Wolfsdorf JI, Jackson RA, Eisenbarth GSJTJop. Distinction between transient hyperglycemia and early insulin-dependent diabetes mellitus in childhood: a prospective study of incidence and prognostic factors. 1993;123(3):347-54.
Eshraghi P, Bagheri S, Kamel SJIJoP. Association of Pediatric Stress Hyperglycemia with Insulin Metabolism Disorders. 2014;2(1):83-7.
Bhisitkul DM, Vinik AI, Morrow AL, She J-X, Shults J, Powers AC, et al. Prediabetic markers in children with stress hyperglycemia. 1996;150(9):936-41.
Weiss SL, Alexander J, Agus MSJPec. Extreme stress hyperglycemia during acute illness in a pediatric emergency department. 2010;26(9):626.
Metsälä J, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM, et al. The association between asthma and type 1 diabetes: a paediatric case-cohort study in Finland, years 1981–2009. International journal of epidemiology. 2018;47(2):409-16.
Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till M. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. European journal of clinical pharmacology. 1998;54(2):141-7.
Smith A, Banks J, Buchanan K, Cheong B, Gunawardena KJQAIJoM. Mechanisms of abnormal glucose metabolism during the treatment of acute severe asthma. 1992;82(1):71-80.
Chang J-S, You Y-H, Park S-Y, Kim J-W, Kim H-S, Yoon K-H, et al. Pattern of stress-induced hyperglycemia according to type of diabetes: a predator stress model. 2013;37(6):475-83.
Association AD. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S66-S76.
Hirshberg E, Larsen G, Van Duker H. Alterations in glucose homeostasis in the pediatric intensive care unit: Hyperglycemia and glucose variability are associated with increased mortality and morbidity. Pediatric Critical Care Medicine. 2008;9(4):361-6.
Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, Wilson DMJP. Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. 2006;118(1):173-9.
Hanefeld M, Sulk S, Helbig M, Thomas A, Köhler CJJods, technology. Differences in glycemic variability between normoglycemic and prediabetic subjects. 2014;8(2):286-90.
Steck AK, Dong F, Taki I, Hoffman M, Klingensmith GJ, Rewers MJ. Early hyperglycemia detected by continuous glucose monitoring in children at risk for type 1 diabetes. Diabetes care. 2014;37(7):2031-3.

Due to technical limitations, table 1 xlsx is only available as a download in the Supplemental Files section.

Table120210209.xlsx

PDF

Version 1

posted 22 Feb, 2021

You are reading this latest preprint version

Stress Hyperglycemia as First Sign of Asymptomatic Type 1 Diabetes: An Instructive Case and Literature Review

Status:

Version 1

Abstract

Figures

Background

Case Presentation

Discussion And Conclusions

Abbreviations

Declarations

References

Table

Supplementary Files

Status:

Version 1